GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Intrinsic Value: Projected FCF

EV Biologics (EV Biologics) Intrinsic Value: Projected FCF : $0.00 (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-21), EV Biologics's Intrinsic Value: Projected FCF is $0.00. The stock price of EV Biologics is $0.5541. Therefore, EV Biologics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for EV Biologics's Intrinsic Value: Projected FCF or its related term are showing as below:

YECO's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.35
* Ranked among companies with meaningful Price-to-Projected-FCF only.

EV Biologics Intrinsic Value: Projected FCF Historical Data

The historical data trend for EV Biologics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Intrinsic Value: Projected FCF Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Intrinsic Value: Projected FCF
- - - - -

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EV Biologics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, EV Biologics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where EV Biologics's Price-to-Projected-FCF falls into.



EV Biologics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



EV Biologics  (OTCPK:YECO) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

EV Biologics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.5541/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of EV Biologics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

By ACCESSWIRE ACCESSWIRE 08-12-2021

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics is now Pink Current

By ACCESSWIRE ACCESSWIRE 06-14-2021